0001839882-24-004093.txt : 20240213 0001839882-24-004093.hdr.sgml : 20240213 20240213080526 ACCESSION NUMBER: 0001839882-24-004093 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240213 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 24622660 BUSINESS ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 BUSINESS PHONE: 212-980-9155 MAIL ADDRESS: STREET 1: 26 MAIN STREET, SUITE 101 CITY: CHATHAM STATE: NJ ZIP: 07928 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 8-K 1 tnxp-8k_021324.htm CURRENT REPORT
false 0001430306 0001430306 2024-02-13 2024-02-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): February 13, 2024

 

 

TONIX PHARMACEUTICALS HOLDING CORP. 

(Exact name of registrant as specified in its charter)

 

Nevada 001-36019 26-1434750

(State or Other Jurisdiction 

of Incorporation) 

(Commission 

File Number)

(IRS Employer 

Identification No.) 

 

26 Main Street, Chatham, New Jersey 07928

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 904-8182

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TNXP The NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On February 13, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced that it engaged Rho, Inc. (“Rho”) to support the Company’s preparation and planned submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration for approval of its Tonmya™ (cyclobenzaprine HCl sublingual tablets) product candidate for the management of fibromyalgia. A copy of the press release that discusses this matter is filed as Exhibit 99.01 and hereto and incorporated herein by reference.

 

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01Other Events.

 

On February 13, 2024, the Company announced that it engaged Rho to support its preparation and planned submission of an NDA for approval of Tonmya™ for the management of fibromyalgia.

 

Forward- Looking Statements

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  

Exhibit

No.

   Description.
   

99.01

104

  

Press Release, dated February 13, 2024

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: February 13, 2024 By: /s/ Bradley Saenger  
  Bradley Saenger
  Chief Financial Officer

 

 

 

 

 EX-99.01 2 ex99-1.htm PRESS RELEASE, DATED FEBRUARY 13, 2024

 

 

Tonix Pharmaceuticals Holding Corp. 8-K

Exhibit 99.1

 

Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia

 

Tonmya™ is a potential new first-line therapy, non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from two Phase 3 trials

 

New Drug Application (NDA) submission to the FDA planned for second half of 2024

 

Fibromyalgia is a chronic pain condition affecting approximately 10 million U.S. adults that typically persists for years or decades

 

CHATHAM, N.J., February 13, 2024 (GLOBE NEWSWIRE) – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it has engaged Rho, Inc. (Rho), a global contract research organization (CRO), to support Tonix’s preparation and planned submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia.

 

“We are excited by our most recent positive Phase 3 study results of Tonmya and look forward to Rho’s support in preparing our NDA,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals. “We intend to meet with the FDA in the first half of this year and to submit our NDA in the second half of the year. We believe we have completed all development work required for the NDA, including CMC requirements and the completion of two positive Phase 3 studies.”

 

Tonmya is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride developed for the management of fibromyalgia. In December 2023, the Company announced highly statistically significant and clinically meaningful topline results in RESILIENT, a second positive Phase 3 clinical trial of Tonmya for the management of fibromyalgia. In the study, Tonmya met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia. Statistically significant and clinically meaningful results were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue and improving overall fibromyalgia symptoms and function. RELIEF, the first positive Phase 3 trial of Tonmya in fibromyalgia, was completed in December 2020. It met its pre-specified primary endpoint of daily pain reduction compared to placebo (p=0.010) and showed activity in key secondary endpoints.

 

“We are delighted in our continued support of Tonix and their Tonmya program,” said Tara Gladwell, President and COO at Rho. “We are hopeful that this work may result in a new treatment for the millions of Americans that suffer from this debilitating, chronic disorder.”

 

About Fibromyalgia

 

Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 6 million to 12 million adults in the U.S., the majority of whom are women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative sleep, fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and mood disturbances, including anxiety and depression. Individuals suffering from fibromyalgia struggle with their daily activities, have impaired quality of life, and frequently are disabled. Physicians and patients report common dissatisfaction with currently marketed products.

 

 

 

 

About Tonmya™ (also known as TNX-102 SL)

 

Tonmya is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride which is designed for daily administration at bedtime with a proposed mechanism of improving sleep quality in fibromyalgia. Tonmya provides rapid transmucosal absorption and reduced production of a long half-life active metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism. As a multifunctional agent with potent binding and antagonist activities at the 5-HT2A-serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic cholinergic receptors, Tonmya is in development as a daily bedtime treatment for fibromyalgia. TNX-102 SL is also in development fibromyalgia-type Long COVID (formally known as post-acute sequelae of COVID-19 [PASC]), alcohol use disorder, and agitation in Alzheimer’s disease. The United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018, Patent No. 10,357,465 in July 2019, and Patent No. 10736859 in August 2020. The Protectic™ protective eutectic and Angstro-Technology™ formulation claimed in the patent are important elements of Tonix’s proprietary Tonmya composition. These patents are expected to provide Tonmya, upon NDA approval, with U.S. market exclusivity until 2034/2035. In addition, Tonix has pending but not issued U.S. patent applications directed to the transmucosal absorption of CBP-HCl, with U.S. market exclusivity expected until 2033, for treating depressive symptoms in fibromyalgia, with U.S. market exclusivity expected until 2032, and for treating pain in fibromyalgia with U.S. market exclusivity expected until 2041.

 

About Rho

 

Rho is a global, privately held contract research organization (CRO) headquartered in Research Triangle Park, a biotech hub in North Carolina, US. Rho provides a full range of drug development services, from program strategy through to clinical trials and marketing applications. Since 1984, Rho has been a trusted partner to some of the most innovative pharmaceutical, biotechnology and medical device companies as well as academic and government organizations. Dedicated to service excellence and cross-functional collaboration, Rho’s therapeutic expertise, employee focus and commitment to strong site relationships change what it means to work with a CRO – accelerating time to market, maximizing ROI, and delivering consistent, smarter and more efficient programs. Experience Rho by following the company on LinkedIn.

 

Tonix Pharmaceuticals Holding Corp.*

 

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA for Tonmya, which has completed two positive Phase 3 studies for the management of fibromyalgia. Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of Tonmya for the management of fibromyalgia in the second half of 2024. TNX-102 SL is being developed to reduce the severity of acute stress reaction and the frequency of acute stress disorder and posttraumatic stress disorder. This trial is being sponsored by the University of North Carolina and received funding support from the U.S. Department of Defense. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and topline results from a proof-of-concept study were reported in the third quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA and received funding from the National Institute on Drug Abuse (NIDA). A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024. Tonix’s rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome (PWS). TNX-2900 has been granted Orphan Drug designation by the FDA and an investigational new drug (IND) application has been cleared to support a Phase 2 study in PWS patients. Tonix’s immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 was initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19. During the fourth quarter of 2023, TNX-1800 was selected by the U.S. National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Project NextGen for inclusion in Phase 1 clinical trials. The infectious disease development portfolio also includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.

 

 

 

 

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

 

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

 

This press release and further information about Tonix can be found at www.tonixpharma.com.

 

Forward Looking Statements

 

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2023, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

 

 

 

 

Investor Contact

 

Jessica Morris

Tonix Pharmaceuticals

investor.relations@tonixpharma.com

(862) 904-8182

 

Peter Vozzo

ICR Westwicke

peter.vozzo@westwicke.com

(443) 213-0505

 

Media Contact

 

Ben Shannon

ICR Westwicke

ben.shannon@westwicke.com

443-213-0495

 

 

 EX-101.SCH 3 tnxp-20240213.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tnxp-20240213_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tnxp-20240213_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 13, 2024
Entity File Number 001-36019
Entity Registrant Name TONIX PHARMACEUTICALS HOLDING CORP.
Entity Central Index Key 0001430306
Entity Tax Identification Number 26-1434750
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 26 Main Street
Entity Address, City or Town Chatham
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07928
City Area Code (862)
Local Phone Number 904-8182
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TNXP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tonixpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tnxp-20240213.xsd tnxp-20240213_lab.xml tnxp-20240213_pre.xml tnxp-8k_021324.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tnxp-8k_021324.htm": { "nsprefix": "TNXP", "nsuri": "http://tonixpharma.com/20240213", "dts": { "schema": { "local": [ "tnxp-20240213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "tnxp-20240213_lab.xml" ] }, "presentationLink": { "local": [ "tnxp-20240213_pre.xml" ] }, "inline": { "local": [ "tnxp-8k_021324.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://tonixpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp-8k_021324.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tnxp-8k_021324.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://tonixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001839882-24-004093-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001839882-24-004093-xbrl.zip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
<+0, .P+ 1 M " ?(6 !T;GAP+3(P,C0P,C$S+GAS9%!+ 0(4 Q0 ( *Q 35C] M' +[_0H ("& 5 " 4X: !T;GAP+3(P,C0P,C$S7VQA M8BYX;6Q02P$"% ,4 " "L0$U8N68N<%D' #;5P %0 M@ %^)0 =&YX<"TR,#(T,#(Q,U]P&UL4$L! A0#% @ K$!-6*$> MMN61%0 ]H\ !( ( !"BT '1N>' M.&M?,#(Q,S(T+FAT 7;5!+!08 !0 % #T! #+0@ ! end XML 16 tnxp-8k_021324_htm.xml IDEA: XBRL DOCUMENT 0001430306 2024-02-13 2024-02-13 iso4217:USD shares iso4217:USD shares false 0001430306 8-K 2024-02-13 TONIX PHARMACEUTICALS HOLDING CORP. NV 001-36019 26-1434750 26 Main Street Chatham NJ 07928 (862) 904-8182 false false false false Common Stock TNXP NASDAQ false